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Pathological complete response (pCR) after chemoradiation therapy 
(CRT) is increasingly reported with a range between 10% and 30%. 
Patients with pCR have been reported to have a favorable oncological 
outcome (LR 1.2% CSS 95.6%) and it rises the doubt that major surgery 
with total mesorectal excision (TME) is probably an overtreatment. 
This is specially true regarding the high rate of short and long-term 
morbidity (evacuative, urinary and sexual disfunction)  associated 
with it. The question is how to pre-operatively predict pCR with an 
high level of accuracy. Clinical complete response (cCR) is not 
homogeneusly defined and is not fully reliable in predicting pCR(25-
85%). Full-Thickness Local Excision (FTLE) after CRT in major 
responders to neoadjuvant treatment should be regarded not as a 
cancer treatment but as the best diagnostic tool to confirm pCR. The 
accuracy of FTLE in the definition of (T) it is ≈ 99% and in ypT0, 
looking at  reported series  it is possible to predict the absence of 
lymph node involvement with an accuracy of ≈ 96%. Clinical trials  to 
confirm validity of a less invasive therapeutic approach are required. 
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Recent insights into the molecular mechanisms underlying tumor cell 
radiosensitivity have led to the identification of a large number of 
potential targets for rational intervention. Blockade of EGFR signaling, 
interference with new blood vessel formation, and inhibition of DNA 
damage repair, are a few examples of attractive strategies to increase 
tumor response in combination with radiation (and/or chemotherapy). 
However, despite many studies on radiation-targeted drug 
combinations, the clinical benefit of these new strategies has been 
small so far. It is therefore essential to consider which possible 
mechanisms underlie this limited success. A series of studies 
demonstrated that multiple factors will have to be considered and 
point to opportunities to optimize the combination radiation-targeted 
agents. 
Focusing on a single target or signaling pathway may be an effective 
strategy for a specific tumor, but not for others. For example, 
targeted inhibition of the BRAF(V600E) oncoprotein is highly effective 
in the treatment of melanoma, but not of BRAF(V600E) mutant colon 
tumors. RNAi genetic screening revealed that blockade of EGFR 
signaling shows strong synergy with BRAF(V600E) inhibition. 
Mechanistically, BRAF(V600E) inhibition causes a rapid feedback 
activation of EGFR, explaining continued proliferation in the presence 
of BRAF(V600E) inhibition. Similarly, a feedback mechanism has been 
described in EGFR-driven cancers in which MEK inhibition leads to 
activation of PI3K/AKT signaling.Thus, targeting multiple pathways 
may be required to obtain sufficient radiosensitizing conditions. 
Normal tissue toxicity limits the therapeutic ratio of any anti-cancer 
therapy, including radiation-targeted drug combinations. A recent 
randomized phase II study at the NKI evaluating cisplatin-based 
chemoradiation with or without cetuximab in locally advanced NSCLC 
demonstrated no survival advantage, but was associated with 
significantly more grade ≥ 3 acute toxicity. 
Scheduling between radiation and targeted agents represents another 
important mechanistic aspect to take into account. This is of 
particular relevance for anti-angiogenic drugs. There are both 
preclinical and clinical data that demonstrate that treating tumors 
with this class of targeted agents is associated with a time window of 
opportunity, characterized by vessel normalization. During this phase 
of improved oxygenation and perfusion, which may differ among 
tumors, radiation (and chemotherapy) will exert their optimal anti-
tumor effect. 
Hitting the right target with a biologically optimal dose discriminates 
radiosensitization from single agent cytotoxicity. Whereas dose 
escalation studies frequently aim at identifying the maximum 
tolerated dose, radiosensitizing strategies require doses of targeted 
agents (or chemotherapy) that sufficiently modulate the predefined 
target. These doses are not necessarily associated with single agents 
dose-limiting toxicity. PARP inhibitors such as olaparib may be 
effective as radiosensitizers at significantly lower doses than required 
to exert single agent activity. It is therefore important to establish 
sensitive biomarkers that assess PARP inhibition in the context of 
radiosensitization efficacy. Such biomarkers for radio-sensitization 
efficacy of PARP inhibitors are currently evaluated in a phase I-II dose-
escalation study in locally advanced NSCLC combining olaparib with 
standard chemoradiation at the NKI. 
In summary, radiation-targeted agent combinations are attractive but 
challenging strategies that require a rational approach and careful 
study design.  
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Modern radiation oncology will require a new synergy between high-
precision radiotherapy protocols and innovative approaches for 
biological optimization of radiation effect. From a clinical 
perspective, new insight into molecular radiobiology will provide a 
unique opportunity for rational patient stratification based on 
actionable tumor targets, enabling the parallel design of next-
generation trials that formally examine the effect of adding targeted 
therapeutics to radiation, together with the critically important 
assessment of radiation dose-volume relationships of both tumor 
response and normal tissue toxicity. In considering the use of systemic 
agents with presumed radiosensitizing activity, this will need 
particular attention in defining patient eligibility. The presentation 
will highlight principles in addressing clinical evaluation of combined-
modality targeted therapeutics and radiotherapy. 
Omes – Pathways to be targeted: On review of 90 recent early-phase 
trials combining targeted therapeutics and radiation, a number of 
actionable tumor signaling pathways involved in tumor proliferation, 
angiogenesis, and hypoxia were found to have been examined, with 
tolerability, safety, and efficacy as study endpoints. In these trials, 
treatment outcome was diverse, ranging from tolerable to significant 
toxicities, and from lack of additional via significant responses to 
unexpected early disease progression. Our review did not specifically 
investigate whether the systemic agents had been evaluated with 
respect to biological mechanisms of radiosensitization in appropriate 
preclinical tumor models prior to the specific clinical studies. 
Omics – Procedures for identifying relevant actionable targets: In 
medical oncology early-phase studies of systemic targeted 
therapeutics, the prevailing gold-standard for patient selection is 
based primarily on the detection of tumor gene aberrations. In 
contrast, in radiotherapy, the composite activities of a range of 
signaling effector proteins determining tumor resistance to radiation 
may conceptually comprise a functional biomarker of actionable 
targets for radiosensitization. Hence, theranostic profiling 
technologies should ideally reflect all interacting signaling pathways 
involved in tumor proliferation, angiogenesis, and hypoxia. Using array 
technology with tyrosine kinase substrates, we have shown that 
composite tumor signaling mediated by high phosphatidylinositol-3-
kinase activity may be a biomarker for treatment stratification in 
rectal cancer patients undergoing neoadjuvant chemoradiotherapy. 
Optimization – Patient eligibility: Treatment protocols should 
minimize the specific detriment of interruption in radiation delivery 
and the consequent negative impact on the probability of tumor 
control. Hence, only patients that are not candidates for curative 
radiotherapy protocols should be regarded as eligible in a trial setting 
of evaluating tolerability of a first-in-human combination of radiation 
with a targeted therapeutic. Of note, in our investigation of recent 
early-phase combined-modality trials, one-third of studies with 
